Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.78 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 2/20 | 0.67 |
| ▸ | MMP9 | P14780 | 2/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.64 |
| ▸ | ITGAV | P06756 | 1/20 | 0.64 |
| ▸ | CPB1 | P15086 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.64 |
| ▸ | TGM2 | P21980 | 3/20 | 0.64 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806151 | 1.00 | FOLH1 (0.78) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL464715 | 1.00 | FOLH1 (0.78) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL11875673 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL4173693 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL4173691 | 0.96 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL18907025 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157463 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL18907028 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157482 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 | |
| SCHEMBL14157462 | 0.95 | FOLH1 (0.72) | FOLH1SIRT2SIRT1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-3988538-B1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | AJINOMOTO CO., INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | AJINOMOTO CO., INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | disclosed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2019-05-23 | — | — | US | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| US-7488755-B2 | Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid | PRESTWICK PHARMACEUTICALS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1529030-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | Prestwick Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016580-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | FOLH1 155/4885SIRT2 3920/4885SIRT1 4379/4885 |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | FOLH1 4283/4885SIRT2 2667/4885SIRT1 3042/4885 |
| US-20230210110-A1 | METHOD FOR INDUCING ENVIRONMENTAL STRESS TOLERANCE IN PLANTS | DAO, ALAD, BCAT1 | FOLH1 2306/4885SIRT2 3556/4885SIRT1 2971/4885 |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | GLRA3, GLRA1, GLRA2 | FOLH1 624/4885SIRT2 3372/4885SIRT1 3485/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | FOLH1 3754/4885SIRT2 2590/4885SIRT1 2095/4885 |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | FOLH1 155/4885SIRT2 3920/4885SIRT1 4379/4885 |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ABCG2, CYP51A1, HACD3 | FOLH1 3851/4885SIRT2 2483/4885SIRT1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.